Table 1 A summary of the clinico-pathological data of the 148 patients: Overall, with and without gene aberrations and with/without TMPRSS2:ERG fusion
From: TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer
All Patients | Patients without gene aberrations | Patients with gene aberrations | Patients with fusion TMPRSS2:ERG | Patients with no fusion TMPRSS2:ERG | |
|---|---|---|---|---|---|
148 | 69 | 79 | 63 | 85 | |
pT stage | |||||
pT2a | 9 | 5 | 4 | 3 | 6 |
pT2b | 12 | 7 | 5 | 4 | 8 |
pT2c | 65 | 34 | 31 | 22 | 43 |
pT3a | 49 | 20 | 29 | 26 | 23 |
pT3b | 13 | 3 | 10 | 8 | 5 |
AGE (years) | 64.37 (47–78) | 64.50 (47–78) | 64.24 (49–76) | 64.27 (49–76) | 64.44 (47–78) |
N stage | |||||
eLND | 122 | 57 | 65 | 53 | 69 |
pN0 | 18 | 8 | 10 | 6 | 12 |
pN1 | 8 | 4 | 4 | 4 | 4 |
PSA before OP (ng/ml) | 8.95 (0.1–110) | 9.39 (0.1–110) | 8.56 (0.71–43.2) | 8.37 (0.71–43.2) | 9.38 (0.1–110) |
GS before OP (N°) | |||||
6 | 62 | 35 | 27 | 21 | 41 |
7 | 78 | 32 | 46 | 38 | 40 |
≥8 | 8 | 2 | 6 | 4 | 4 |
PSA 1 month after OP ng/ml | 0.26 (0.0–20) | 0.42 (0.0–20) | 0.11 (0.00–2.8) | 0.14 (0.00–2.8) | 0.35 (0.001–20) |
GS after OP (N°) | |||||
6 | 47 | 28 | 19 | 15 | 32 |
7 | 88 | 36 | 52 | 42 | 46 |
≥8 | 13 | 5 | 8 | 6 | 7 |